Recombinant E. Coli Ecl19; Recombinant E. Coli Bl21
98 adverse event reports submitted to the FDA
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
98
Total Reports
11
Deaths Reported
1120.0%
Death Rate
Active Ingredients
Recombinant E. Coli Ecl19; Recombinant E. Coli Bl21
Administration Routes
Subcutaneous
Species Affected
Dog 98
Most Affected Breeds
Retriever - Labrador 10
Shepherd Dog - German 7
Bulldog - French 5
Bulldog 5
Mixed (Dog) 4
Terrier - Jack Russell 4
Retriever - Golden 4
Retriever (unspecified) 3
Shepherd Dog - Australian 3
Collie - Border 3
Most Reported Reactions
Lethargy (see also Central nervous system depression in 'Neurological') 33
Vomiting 25
Lack of efficacy (ectoparasite) - tick NOS 15
Other abnormal test result NOS 13
Anorexia 11
Diarrhoea 10
Fever 7
Injection site pain 7
Shaking 7
Hives (see also 'Skin') 7
Lameness 6
Musculoskeletal disorder NOS 6
Outcome Breakdown
Ongoing
50 (51.0%)
Recovered/Normal
32 (32.7%)
Died
6 (6.1%)
Outcome Unknown
5 (5.1%)
Euthanized
5 (5.1%)
Source: FDA Center for Veterinary Medicine — Adverse Event Reports. Data reflects voluntary submissions and may not represent actual incidence rates.